[HuEPO treatment of anemia in preterm infants].
The aim of this study is to evaluate how many blood transfusions can be saved by the treatment of anemia in preterm infants (eg < or = 33 weeks) with HUEPO. VLBW infants are at high risk of receiving blood transfusions, following the blood transfusion criteria most applied (45-50% of VLBW infants need blood transfusions). A review of the most recent studies shows that we can save a remarkable number and quantity of blood transfusions in the VLBW infants treated with HUEPO.
Galligani
L
L
Sezione di Assistenza Neonatale, Ospedale degli Infermi di Biella.
Perona
A
A
D000740:Anemia / Q000628:therapy*; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin
Terapia con HUEPO nell'anemia del pretermine.